5-fluorouracil

Hey #MedTwitter what’s your take for 3rd line treatment in HER2 3+ gallbladder #cancer currently achieving stable disease under FOLFIRI? @DrAngelaLamarca @ArndtVogel @SaborowskiAnna @JavleMilind @pashtoonkasi @MPishvaian @SebLange #PrecisionMedicine @OncoAlert 🚨 (@BenWestphalen)

Optimal maintenance strategy following FOLFOX + anti-EGFR in RAS WT mCRC: individual patient data pooled analysis of 4 clinical trials @OncologyAdvance https://t.co/m0C5Z9Vc3S 👉Low evidence, overall FU/LV + anti-EGFR preferred maintenance, stop & go stillan option @myESMO… https://t.co/VaNKlHpNf3 (@ArndtVogel)

Here is our international collaborative work on FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer ⁦@AnnSurgOncol⁩ ⁦@SocSurgOnc⁩ ⁦@SSATNews⁩ ⁦@FlavioRochaMD⁩ ⁦ https://t.co/4ALnMZQuI3 (@SyedAAhmad5)

5-FU (in the form of tegafur for NSCLC) is used for all of those tumors (@FGB86309474)

Intermittent or continuous FOLFIRI/PANI for 1st line RAS/BRAF WT mCRC: update of survival/toxicity & preliminary results of GA from IMPROVE @ #WCGIC2023 👉Stop & go seems feasible, less toxicity 👉Resistente mechanisms not yet resolved @WCGIC @myESMO @OncoAlert (@ArndtVogel)

Intermittent or continuous FOLFIRI/PANI for 1st line RAS/BRAF WT mCRC: update of survival/toxicity & preliminary results of GA from IMPROVE @ #WCGIC2023 👉Stop & go seems feasible, less toxicity 👉Resistente mechanisms not yet resolved @WCGIC @myESMO @OncoAlert (@ArndtVogel)

👍#Flashback @JCO_ASCO @ASCO #CRCsm Almost 20 years ago, these 2 trials defined the tx of #mCRC & have stood the test of time to this day! 📌 N971 - Goldberg et al ➡️ established FOLFOX in 🇺🇸 🇨🇦 📌 Tournigand sequencing study ➡️ established the use of FOLFOX/FOLFIRI 🙏 to… https://t.co/Jf1E0ttxRA (@GillSharlene)

👍#Flashback @JCO_ASCO @ASCO #CRCsm Almost 20 years ago, these 2 trials defined the tx of #mCRC & have stood the test of time to this day! 📌 N971 - Goldberg et al ➡️ established FOLFOX in 🇺🇸 🇨🇦 📌 Tournigand sequencing study ➡️ established the use of FOLFOX/FOLFIRI 🙏 to… https://t.co/NRaxayz0f4 (@GillSharlene)

We're excited for Dr. Alfonso De Stefano's (@alfdestefano) presentation on "Intermittent or continuous panitumumab + FOLFIRI for first-line treatment of patients with RAS/BRAF wild type metastatic #ColorectaLCancer" at #WCGIC2023 tomorrow! 🤩 Program: https://t.co/ln4c4FaZ9J (@Intestinal_Cell)

#WCGIC2023 💊 Emerging 🎯 in #GI cancer 🪑Dr. Van Cutsem + Dr. Carnero 🗣️ Dra. Obermannova 🎯 Claudin 18.2 ❌ Not predictive of #PFS for #IO #CT ✔️ Zolbetuximab and 👉🏼EOX #FAST PFS 9 vs 5.7m 👉🏼mFOLFOX6 #SPOTLIGHT OS 18.2 vs 15.5m 👉🏼CAPOX #GLOW OS 14.4 vs 12.2m @WCGIC @myESMO (@DrMirallas)

#抗FGFR2b抗体 #bemarituzumab とmFOLFOX6の併用療法が、免疫組織化学染色（IHC）でFGFRb発現2+/3+が腫瘍細胞の10％以上を占める進行 #胃がん の1次治療としてmFOLFOX6のみよりも高い有効性を示す可能性が明らかとなりました。 #WCGIC2023 https://t.co/sYzEOkWodi (@cancer_navi)

Presenting our interim analysis of the US experience in second-line nanoliposomal irinotecan/5-FU/leucovorin in advanced #biliarycancer #WCGIC2023 #Barcelona @WCGIC @myESMO @RueschCenter @anita_turk @RuthHe12 @mnoel3232 @marshalj23 @DrKatePedersen @SitemanCenter (@benweinbergmd)

FOLFOXIRI plus Cetuximab or Bevacizumab as 1st-line Treatment of BRAFV600E-mut #coloncancer FIRE-4.5 trial now out in @JCO_ASCO https://t.co/Dme3hX2HeP @StintzingS 👉 if using triplet in mBRAF mCRC, combination with Bev remains the preferable treatment choice @OncoAlert 🚨 (@heinrich_kat)

#OpenAccess in @OncJournal: @FoundationATCG data from >8,000 #PancreaticCancer cases, ~1200 with 1st line Rx data (via @flatironhealth) A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic #PancreaticCancer https://t.co/fDmyhBvWIX @MPishvaian @PancPathologist (@Aiims1742)

Annual Updates in Oncology 2023 - Dr. @RyanCMassa presents updates in GI tumors 1. Prospect Trial, Plenary FOLFOX w/ selective chemoRT non inferior to CRT 2. Fruquintinib in CRC 3. NORPACT-01: *negative* neoadj study in pancreas ca @PennCancer @PennMedicine (@CharuAggarwalMD)

16/21 #TumorBoardTuesday ➡️Finally, moving on to the management of advanced #colorectalcancer & rectal Ca, which is getting very complicated😲 ➡️First, Dr. Antoniotti 🗣️an update of the AtezoTRIBE trial in which patients with mCRC were randomized to FOLFOXIRI-Bev +/- Atezo (@MPishvaian)

Congrats~🎊 to patients with advanced GEJ & #GastricCancer & #SPOTLIGHT team @KoheiShitara @FlorianLordick @ILSONDavid #zolbetuximab + mFOLFOX6 in tumors #HER2 (-) #CLDN18.2 show ⬆️OS & PFS📈 vs SOC mFOLFOX6 met endpoints HR 0.75; mOS 18.2m vs 15.5m, p=0.005 🖊️87% had PD-L1 CPS<5 (@CentralParkWMD)

PROSPECT: Ph3 RCT neoadjuvant chemoXRT vs neoadjuvant FOLFOX chemo w/selective use of chemoXRT, followed by total mesorectal excision (TME) for Tx of locally advanced rectal cancer (LARC) (@ALLIANCE_org N1048) - @debschrag et al #ASCO23 LBA2 https://t.co/nP8YNpWmEA #crcsm #radonc (@mtmdphd)

When should you switch from FOLFIRINOX to Gem/ nab-PAC for rectangle pancreas cancer? ⁦@AnnSurgOncol⁩ ⁦@McMastersKelly⁩ ⁦@isteaus⁩ ⁦@MedicalCollege⁩ ⁦@mkatzmd⁩ https://t.co/9yftkuT95Q (@SyedAAhmad5)

#colorectalcancer #chemotherapy #Fluoropyrimidine 👏👏Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects 🎯https://t.co/ZUFRmlSzzx @fsgcrc @FightCRC @abbassmohd @josepereag @NancyYouMD @DrZuriMurrell @DrZuriMurrell (@cdrjournal)

📢 ASCO 2023 Pancreatic Cancer 🎗️ 🧪 A recent study compared the #NALIRIFOX and #FOLFIRINOX regimens as first-line treatments for advanced pancreatic cancer. 🩺 @Mom_enji @IstTumori #AdvancedPancreaticCancer #ASCO23 🔗 https://t.co/Xi3OmEYhug (@oncologytube)

Watch this ASCO video of @giconnectInfo expert @StintzingS discussing how liquid biopsy is relevant in verifying mutational status in patients with metastatic #CRC and first-line treatment of #FOLFIRI + #cetuximab for RAS-WT disease https://t.co/Pwl5oYGskn #MedEd #mCRC (@giconnectInfo)

The #OncoAlertTopTweet 🚨 Day 4 of #ASCO23 🌐 An honor to present our @OncoAlert 🚨 #PancreaticCancer faculty @BenWestphalen discussing: NORPACT1 Short NeoAdj FOLFIRINOX Vs Surgery Best, @weoncologists (@OncoAlert)

@BasselElRayesMD shows: 1) PhIII SOLSTICE in lonsurf+bev = cape-bev #1L mCRC ineligible for intensive chemo, 2) CodeBreaK 101 soto+FOLFIRI-pmab in pretreated #KRASG12C mCRC ORR 55% (0 CRs), 3) FIH PhI WNT/porcupine inh CGX1321+pembro 71% SD w/RSPO/RNF43 fusion #ASCO23 @OncoAlert (@jgong15)

Catching up on PROSPECT: A randomized ph III trial of neoadj Chemo-RT vs neoadj FOLFOX with selective use of chemo-RT, => by TME for tx of locally advanced rectal cancer, plenary talk by Dr. @debschrag #ASCO23 #rectalcancer Nice simple language summary at https://t.co/e9wmbmMibB (@manjuggm)

Case#2 #ctDNA in the Management of Early Colorectal Cancer:The Time Has Come! #ASCO23 #CRCSMGreat case! ctDNA (-) now Wwyd? Duration of adj IO? Dr.P: 1 or 2Y seems overkill, gave 6M Dr.T: repeat ctDNA. IO not 2Y, 6m-1Y maybe or 9m? If ctDNA (+), wwyd? Dr. T: no FOLFOX, Combi IO (@manjuggm)

Validation of the PDACai signature in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC) @ASCO. @MPishvaian @edikb @PanCAN #mPDAC #ASCO23 #Perthera #PrecisionMedicine (@Perthera)

Plenary2️⃣ PROSPECT Trial Selective omission of radiation for those responding to upfront systemic therapy (FOLFOX). ☢️❌ #ASCO23 @OncoAlert Now published @NEJM 📌https://t.co/YePVNXIDnU 5-year disease free survival! 2011 to 2018! @ALLIANCE_org @EileenMOReilly #CRCSM (@pashtoonkasi)

Dear Colleagues at #ASCO23 An honor to present our @OncoAlert 🚨 #PancreaticCancer faculty @BenWestphalen 🇩🇪 discussing: NORPACT1 Short NeoAdj FOLFIRINOX Vs Surgery Best, @weoncologists @Aiims1742 @ArndtVogel @CathyEngMD @manjuggm @ARosen380 @stacy_hurt @GraceCordovano… https://t.co/6261sp5Efl (@OncoAlert)

Dear Colleagues at #ASCO23 An honor to present our @OncoAlert 🚨 #PancreaticCancer faculty @BenWestphalen 🇩🇪 discussing: NORPACT1 Short NeoAdj FOLFIRINOX Vs Surgery Best, @weoncologists @Aiims1742 @ArndtVogel @CathyEngMD @manjuggm @ARosen380 @stacy_hurt @GraceCordovano… https://t.co/CDEQPJCeuZ (@OncoAlert)

@StintzingS PhIII FIRE-4 #1L RAS WT #mCRC 13% RAS MT/7% BRAF MT in liquid bx despite WT on tissue predicts ORR, PFS, OS w/double WT on baseline liquid+tissue NGS w/FOLFIRI+cetux +/- switch maint. 19.4% emerging RAS mt w/cont cetux med 48.3 wks exposure w/no OS impact @OncoAlert (@jgong15)

Looks like re-challenge worked pretty well in the small numbers presented. I don’t understand the taxane vs 5FU reference in NSCLC? (@Clavikul)

.@TGeorgeMD is a coauthor on the PROSPECT trial study that @UFHealth participated in, showing neoadjuvant FOLFOX was noninferior to chemoradiotherapy for disease-free survival for patients with #RectalCancer. #ASCO23 Read more in the @nytimes: https://t.co/hqPfcdSU13 (@UFHealthCancer)

This trial supports omission of neoadjuant FOLFOX in well selected rectal cancer patients. No detriment in outcomes, lower adverse effects - short and long term as well as reduced time toxicity all favouring CRT. (@learningonco)

Alliance N1048 PROSPECT rectal cancer trial of neoadjuvant 5FUCRT vs FOLFOX plus selective use of 5FUCRT. Noninferior DFS. Longer-term PRO-CTCAE & other PROs tip the scale to FOLFOX! https://t.co/9FZv8ooAKw @ALLIANCE_org @debschrag @EthanBasch1 @GitaThanaMD (@BiostatGirl)

Preoperative Treatment of Locally Advanced Rectal Cancer (PROSPECT) https://t.co/2xQxsAPmzL - preop FOLFOX was noninferior to preop chemoXRT with respect to DFS - both groups were similar with respect to OS & local recurrence @EileenMOReilly @ColonCancerDoc #ASCO23 (@Aiims1742)

CRC oral session on the updated and OS results of the AtezoTRIBE study by GONO. Again confirmation that Immunoscore IC is able to select patients with immunesensitive pMMR/MSS mCRC and PFS/OS benefit from the addition of atezo to FOLFOXIRI/bev. @carlottanto1 @ChiaraCrem1 (@FoundationGono)

Now live: Upper GI, hepato-biliary & pancreatic oral abstracts. Looking forward to updates from NAPOLI-3 & the long awaited NORPACT-1 trial on neoadjuvant FOLFIRINOX in #pancreaticcancer Here with me @heinrich_kat Friendly Faces #ASCO23 😀 #pancsm 💜 @OncoAlert 🚨 (@BenWestphalen)

Validation of the PDACai signature in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC). https://t.co/wAL7n7LC7e Visit our poster session #ASCO23 @MPishvaian @edikb (@Perthera)

The #OncoAlertTopTweet 🚨 Day1⃣of #ASCO23 🇺🇸 Tweet by our OncoAlert faculty @BenWestphalen short course neoadjuvant FOLFIRINOX did not improve OS in #patients w resectable #PancreaticCancer in NORPACT-1 w SHORTER survival in the neoadjuvant arm Best @weoncologists (@OncoAlert)

A quick google reveals a paper where a person living with metastatic colon cancer got 72 cycles of FOLFIRINOX and counting. I did the math and now I need something for nausea. (@EricTSEA)

Huge for colon cancers too!! Especially with 5-FU on national shortage!! (@hungoverham)